全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Advanced Hepatocellular Carcinoma with Subtotal Occlusion of the Inferior Vena Cava and a Right Atrial Mass

DOI: 10.1155/2013/489373

Full-Text   Cite this paper   Add to My Lib

Abstract:

Hepatocellular carcinoma usually metastasizes to regional lymph nodes, lung, and bones but can rarely invade the inferior vena cava with intravascular extension to the right atrium. We present the case of a 75-year-old man who was admitted for generalized oedema and was found to have advanced HCC with invasion of the inferior vena cava and endovascular extension to the right atrium. In contrast to the great majority of hepatocellular carcinoma, which usually develops on the basis of liver cirrhosis due to identifiable risk factors, none of those factors were present in our patient. 1. Introduction Primary hepatocellular carcinoma (HCC) is a quite uncommon tumor in North America and Western Europe but is the fifth most common cancer worldwide and the third leading cause of cancer-related death [1, 2]. Most cases of HCC occur in patients with chronic liver disease or preexisting liver cirrhosis. Common causes for liver cirrhosis are chronic alcoholic liver disease or chronic viral hepatitis due to hepatitis B virus or hepatitis C virus infection [2]. Other risk factors for the development of HCC are metabolic diseases like hemochromatosis or alpha1-antitrypsin deficiency, autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis), and aflatoxin exposition [1, 3–5]. The incidence of HCC shows striking variations between different geographic regions and among different racial and ethnic background within the same country, suggesting a crucial role of genetic and environmental factors in the pathogenesis of HCC [6, 7]. HCC is an aggressive tumor and can show extensive metastazation. It usually metastasizes to regional lymph nodes, lung, or bone but sometimes shows invasion of major blood vessels with endovascular extension [8, 9]. In this report, we present the rare case of an advanced hepatocellular carcinoma with invasion of the inferior vena cava and intravascular extension to the right atrium in a patient without any preexisting liver disease. 2. Case Report A 75-year-old Caucasian man presented to the emergency room of our hospital for dyspnea and new onset generalized oedema rapidly progressing over one week. The patient was known for stable coronary artery disease, paroxysmal atrial fibrillation with oral anticoagulation, chronic obstructive bronchitis, hypertension, and dyslipidemia. He had stopped smoking 3 years before, had no history of alcoholism, and had never taken illegal drugs. Vital signs at presentation were stable. The patient was afebrile and not in respiratory distress. Physical examination revealed generalized oedema

References

[1]  A. I. Gomaa, S. A. Khan, M. B. Toledano, I. Waked, and S. D. Taylor-Robinson, “Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4300–4308, 2008.
[2]  S. Caldwell and S. H. Park, “The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology,” Journal of Gastroenterology, vol. 44, supplement 19, pp. 96–101, 2009.
[3]  K. D. Fairbanks and A. S. Tavill, “Liver disease in alpha 1-antitrypsin deficiency: a review,” American Journal of Gastroenterology, vol. 103, no. 8, pp. 2136–2141, 2008.
[4]  M. C. Kew, “Hepatic iron overload and hepatocellular carcinoma,” Cancer Letters, vol. 286, no. 1, pp. 38–43, 2009.
[5]  T. Watanabe, K. Soga, H. Hirono et al., “Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis,” World Journal of Gastroenterology, vol. 15, no. 2, pp. 231–239, 2009.
[6]  M. I. F. Shariff, I. J. Cox, A. I. Gomaa, S. A. Khan, W. Gedroyc, and S. D. Taylor-Robinson, “Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics,” Expert Review of Gastroenterology and Hepatology, vol. 3, no. 4, pp. 353–367, 2009.
[7]  C. J. Chen, M. W. Yu, and Y. F. Liaw, “Epidemiological characteristics and risk factors of hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 12, supplement 9-10, pp. S294–S308, 1997.
[8]  J. Y. Chang, W. S. Ka, T. Y. Chao, T. W. Liu, T. R. Chuang, and L. T. Chen, “Hepatocellular carcinoma with intra-atrial tumor thrombi: a report of three cases responsive to thalidomide treatment and literature review,” Oncology, vol. 67, no. 3-4, pp. 320–326, 2004.
[9]  A. D. Sung, S. Cheng, J. Moslehi, E. P. Scully, J. M. Prior, and J. Loscalzo, “Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature,” American Journal of Cardiology, vol. 102, no. 5, pp. 643–645, 2008.
[10]  H. A. Edmondson and P. E. Steiner, “Primary carcinoma of the liver: a study of 100 cases among 48,900,” Cancer, vol. 7, no. 3, pp. 462–503, 1954.
[11]  Y. Kato, N. Tanaka, and K. Kobayashi, “Growth of hepatocellular carcinoma into the right atrium. Report of five cases,” Annals of Internal Medicine, vol. 99, no. 4, pp. 472–474, 1983.
[12]  S. Ohwada, Y. Tanahashi, Y. Kawashima et al., “Surgery for tumor thrombi in the right atrium and inferior vena cava of patients with recurrent hepatocellular carcinoma,” Hepato-Gastroenterology, vol. 41, no. 2, pp. 154–157, 1994.
[13]  G. S. W. Chan, W. K. Ng, I. O. L. Ng, and P. Dickens, “Sudden death from massive pulmonary tumor embolism due to hepatocellular carcinoma,” Forensic Science International, vol. 108, no. 3, pp. 215–221, 2000.
[14]  J. Sa?sse, J. Hardwigsen, P. Castellani, T. Caus, and Y. P. Le Treut, “Budd-Chiari syndrome secondary to intracardiac extension of hepatocellular carcinoma. Two cases treated by radical resection,” Hepato-Gastroenterology, vol. 48, no. 39, pp. 836–839, 2001.
[15]  T. P. Tsai and J. M. Yu, “Minimally invasive cardiac surgery for resection of right atrial hepatic tumor in an octogenarian,” Chinese Medical Journal, vol. 65, no. 7, pp. 345–347, 2002.
[16]  Y. Dazai, T. Katoh, I. Katoh, S. Sueda, and R. Yoshida, “Effectiveness of chemoembolization therapy for metastatic right atrial tumor thrombus associated with hepatocellular carcinoma,” Chest, vol. 96, no. 2, pp. 434–436, 1989.
[17]  Y. Kashima, M. Miyazaki, H. Ito et al., “Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with extensive tumour thrombus through the hepatic vein,” Journal of Gastroenterology and Hepatology, vol. 14, no. 9, pp. 922–927, 1999.
[18]  T. Yau, P. Chan, R. Epstein, and R. T. Poon, “Evolution of systemic therapy of advanced hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 14, no. 42, pp. 6437–6441, 2008.
[19]  J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008.
[20]  T. Yau, P. Chan, H. Wong et al., “Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma,” Oncology, vol. 72, supplement 1, pp. 67–71, 2007.
[21]  M. Pinter, M. Wichlas, K. Schmid et al., “Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 10, pp. 1012–1019, 2008.
[22]  S. H. Han, S. H. Park, J. H. Kim et al., “Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study,” Korean Journal of Internal Medicine, vol. 21, no. 4, pp. 225–229, 2006.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413